% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Metzenmacher:294383,
      author       = {M. Metzenmacher and G. Zaun and M. Trajkovic-Arsic$^*$ and
                      P. Cheung$^*$ and T. M. Reissig$^*$ and H. Schürmann$^*$
                      and N. von Neuhoff and G. O'Kane and S. Ramotar and A. Dodd
                      and S. Gallinger and A. Muckenhuber$^*$ and J. J. Knox and
                      V. Kunzmann and P. A. Horn and J. Hoheisel$^*$ and J.
                      Siveke$^*$ and S. S. Lueong$^*$},
      title        = {{M}inimally invasive determination of pancreatic ductal
                      adenocarcinoma ({PDAC}) subtype by means of circulating
                      cell-free {RNA}.},
      journal      = {Molecular oncology},
      volume       = {19},
      number       = {2},
      issn         = {1574-7891},
      address      = {Hoboken, NJ},
      publisher    = {John Wiley $\&$ Sons, Inc.},
      reportid     = {DKFZ-2024-02216},
      pages        = {357-376},
      year         = {2025},
      note         = {2025 Feb;19(2):357-376},
      abstract     = {Pancreatic ductal adenocarcinoma (PDAC) comprises two
                      clinically relevant molecular subtypes that are currently
                      determined using tissue biopsies, which are spatially biased
                      and highly invasive. We used whole transcriptome sequencing
                      of 10 plasma samples with tumor-informed subtypes,
                      complemented by proteomic analysis for minimally invasive
                      identification of PDAC subtype markers. Data were validated
                      in independent large cohorts and correlated with treatment
                      response and patient outcome. Differential transcript
                      abundance analyses revealed 32 subtype-specific,
                      protein-coding cell-free RNA (cfRNA) transcripts. The
                      subtype specificity of these transcripts was validated in
                      two independent tissue cohorts comprising 195 and 250 cases,
                      respectively. Three disease-relevant cfRNA-defined subtype
                      markers (DEGS1, KDELC1, and RPL23AP7) that consistently
                      associated with basal-like tumors across all cohorts were
                      identified. In both tumor and liquid biopsies, the
                      overexpression of these markers correlated with poor
                      survival. Moreover, elevated levels of the identified
                      markers were linked to a poor response to systemic therapy
                      and early relapse in resected patients. Our data indicate
                      clinical applicability of cfRNA markers in determining tumor
                      subtypes and monitoring disease recurrence.},
      keywords     = {PDAC (Other) / cfRNA (Other) / liquid biopsy (Other) /
                      subtype (Other) / therapy (Other)},
      cin          = {ED01 / MU01 / B070},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331 / I:(DE-He78)MU01-20160331 /
                      I:(DE-He78)B070-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39478658},
      doi          = {10.1002/1878-0261.13747},
      url          = {https://inrepo02.dkfz.de/record/294383},
}